Lab leader, Immunology
- Employer
- Innovent Biologics
- Location
- Maryland
- Posted Date
- Oct 24, 2021
Job Details
Lab leader, Immunology
Report Line: VP
Location: U.S. MD / Suzhou, Jiangsu, China / Shanghai, China
Job responsibilities
- Lead discovery efforts from target nomination, validation through pipeline development. Independently conceive, execute experiments and analyze data for proof of concept and mechanism of action studies.
- Manage a research team to understand the mechanisms of immune disorders including, but not limited to, asthma, COPD, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, type 1 diabetes, psoriasis and multiple sclerosis.
- Establish and sustain cross-functional collaborations internally and externally with industrial and academic partners.
- Actively contribute to the research community through publications and conference presentations. Supervise staff members and foster a rigorous and dynamic research environment within team.
Qualifications
- PhD with at least 3 years’ postdoctoral training in immunology or inflammation discipline. Industrial experience preferred. Experience with co-targeting desired.
- Tracked records of original contributions to his/her field, evidenced by high profile first-author publications.
- Hands-on immunological skillsets, demonstrated expertise in advanced flow cytometry, immune cell functional assays and in vivo disease models.
- Excellent communication and interpersonal skills. Agility and adaptability in a fast-paced environment.
Please apply with brief cover letter and CV
Job Type: Full-time
Contacts
Contact People: Lucy Zhang (US) / Katherine Cheng (China)
Tel: 1-301 578 2600 (US) / 0086-135 6471 9010 (China)
E-mail: Lucy.zhang@innoventbio.com (US)
katherine.cheng@innoventbio.com (China)
Company
Excellent Employment Opportunities Available at Innovent Biologics
Established in 2011, Innovent is committed to developing, manufacturing, and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases, and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 5 assets in Phase III or pivotal clinical trials, and additional 14 molecules in to clinical trials. TYVYT® was included in the National Reimbursement Drug List (NRDL) in 2019 as the only PD-1 in that year and was also the first PD-1 inhibitor included in NRDL historically. Innovent has built a biopharmaceutical production facility that operates under global standards. The design and operation of the clinical and commercial facilities are in compliance with the cGMP standards of NMPA, FDA, and EMA. The existing production lines have already passed GMP audits by an international pharmaceutical company. Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic cooperation with Eli Lilly, Adimab, Incyte, Hanmi and other international pharmaceutical companies.
Innovent is genuinely recruiting the talents domestically and internationally. You are more than welcome to join us, where the sky is the limit.
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert